Patents Assigned to OBLIQUE THERAPEUTICS AB
  • Patent number: 11912765
    Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: February 27, 2024
    Assignee: OBLIQUE THERAPEUTICS AB
    Inventors: Owe Orwar, Carolina Trkulja
  • Publication number: 20230109318
    Abstract: The present invention relates to antibodies that bind to certain oncogenic mutant forms of KRAS. The invention also relates to certain epitopes of oncogenic mutant forms of KRAS. The invention also relates to immunoconjugates and compositions comprising such antibodies. The invention also provides methods of producing such antibodies. The invention further provides the use of such antibodies for therapeutic purposes, for example in the treatment of cancer.
    Type: Application
    Filed: February 24, 2021
    Publication date: April 6, 2023
    Applicant: OBLIQUE THERAPEUTICS AB
    Inventors: Carolina TRKULJA, Max DAVIDSON, Owe ORWAR
  • Patent number: 11408883
    Abstract: The present invention relates to methods of identifying an epitope on a protein that can be bound by an antibody. Methods of the invention typically involve a step of limited or restricted proteolysis of a protein using a single first protease or a combination of first proteases, and a further proteolysis step using a single second protease or combination of second proteases. The invention also relates to identified epitopes and to antibodies which bind to epitopes that have been identified by methods of the invention.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: August 9, 2022
    Assignee: OBLIQUE THERAPEUTICS AB
    Inventors: Owe Orwar, Carolina Trkulja, Max Davidson, Jessica Hägglund
  • Publication number: 20220119348
    Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings provided in the description, which compounds are useful in the treatment of cancers.
    Type: Application
    Filed: October 29, 2021
    Publication date: April 21, 2022
    Applicant: Oblique Therapeutics AB
    Inventors: Benjamin Pelcman, Edgars Suna, William Stafford, Martins Priede
  • Publication number: 20220073607
    Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.
    Type: Application
    Filed: September 29, 2021
    Publication date: March 10, 2022
    Applicant: OBLIQUE THERAPEUTICS AB
    Inventors: Owe ORWAR, Carolina TRKULJA
  • Patent number: 11208384
    Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3, R4 and n have meanings provided in the description, which compounds are useful in the treatment of cancers.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: December 28, 2021
    Assignee: Oblique Therapeutics AB
    Inventors: Benjamin Pelcman, Owe Orwar, William Stafford, Kjell Andersson
  • Patent number: 11168069
    Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings provided in the description, which compounds are useful in the treatment of cancers.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: November 9, 2021
    Assignee: Oblique Therapeutics AB
    Inventors: Benjamin Pelcman, William Stafford
  • Patent number: 11161901
    Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: November 2, 2021
    Assignee: OBLIQUE THERAPEUTICS AB
    Inventors: Owe Orwar, Carolina Trkulja
  • Patent number: 11161815
    Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings provided in the description, which compounds are useful in the treatment of cancers.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: November 2, 2021
    Assignee: Oblique Therapeutics AB
    Inventors: Benjamin Pelcman, Edgars Suna, William Stafford, Martins Priede
  • Patent number: 11028067
    Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings provided in the description, which compounds are useful in the treatment of cancers.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: June 8, 2021
    Assignee: Oblique Therapeutics AB
    Inventors: Benjamin Pelcman, Edgars Suna, William Stafford, Martins Priede
  • Publication number: 20200041499
    Abstract: The present invention relates to methods of identifying an epitope on a protein that can be bound by an antibody. Methods of the invention typically involve a step of limited or restricted proteolysis of a protein using a single first protease or a combination of first proteases, and a further proteolysis step using a single second protease or combination of second proteases. The invention also relates to identified epitopes and to antibodies which bind to epitopes that have been identified by methods of the invention.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 6, 2020
    Applicant: OBLIQUE THERAPEUTICS AB
    Inventors: Owe ORWAR, Carolina TRKULJA, Max DAVIDSON, Jessica HÄGGLUND
  • Publication number: 20190194320
    Abstract: The present invention relates to methods of identifying an epitope on a protein that can be bound by an antibody. Methods of the invention typically involve a step of limited or restricted proteolysis of a protein and the identification of sites on the protein that are cut by the protease(s) used. The invention also relates to antibodies which bind to epitopes that have been identified by methods of the invention.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 27, 2019
    Applicant: OBLIQUE THERAPEUTICS AB
    Inventors: Owe ORWAR, Carolina TRKULJA, Max DAVIDSON
  • Publication number: 20180111990
    Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.
    Type: Application
    Filed: March 31, 2016
    Publication date: April 26, 2018
    Applicant: OBLIQUE THERAPEUTICS AB
    Inventors: Owe ORWAR, Carolina TRKULJA